- Home
- ENGN
ENGN
enGene Holdings Inc.
as 05-20-2024 11:31am EST
$.
-
$.
-.%
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
| Founded: | 1999 | Country: | Canada |
| Employees: | N/A | City: | SAINT-LAURENT |
| Market Cap: | 572.4M | IPO Year: | N/A |
| Target Price: | $34.40 | AVG Volume (30 days): | 63.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $6.69 - $47.17 | Next Earning Date: | 03-11-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Share on Social Networks:
Latest enGene Holdings Inc. News
ENGN Breaking Stock News: Dive into ENGN Ticker-Specific Updates for Smart Investing
Business Wire
5 days ago
enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors
CNW Group
18 days ago
enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American Urology Association 2024 Annual Meeting
Argus Research
a month ago
Daily – Vickers Top Buyers & Sellers for 04/23/2024
CNW Group
a month ago
/C O R R E C T I O N -- enGene Inc./
PR Newswire
a month ago
/C O R R E C T I O N -- enGene Inc./
PR Newswire
2 months ago
enGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress
CNW Group
3 months ago
enGene To Present at the Leerink Partners Global Biopharma Conference
PR Newswire
3 months ago